CR20180105A - Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos - Google Patents

Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos

Info

Publication number
CR20180105A
CR20180105A CR20180105A CR20180105A CR20180105A CR 20180105 A CR20180105 A CR 20180105A CR 20180105 A CR20180105 A CR 20180105A CR 20180105 A CR20180105 A CR 20180105A CR 20180105 A CR20180105 A CR 20180105A
Authority
CR
Costa Rica
Prior art keywords
diacums
bio
join
same
specific monovalent
Prior art date
Application number
CR20180105A
Other languages
English (en)
Spanish (es)
Inventor
Ezio Bonvini
Ling Huang
Leslie S Johnson
Gurunadh Reddy Chichili
Paula A Moore
Ralph Alderson
Kalpana Shah
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of CR20180105A publication Critical patent/CR20180105A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CR20180105A 2015-08-17 2016-08-12 Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos CR20180105A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562206051P 2015-08-17 2015-08-17
US201662280318P 2016-01-19 2016-01-19
PCT/US2016/046680 WO2017030926A1 (en) 2015-08-17 2016-08-12 Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof

Publications (1)

Publication Number Publication Date
CR20180105A true CR20180105A (es) 2018-06-12

Family

ID=58051498

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20180105A CR20180105A (es) 2015-08-17 2016-08-12 Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos

Country Status (21)

Country Link
US (1) US20190002563A1 (enExample)
EP (1) EP3337507A4 (enExample)
JP (1) JP2018523686A (enExample)
KR (1) KR20180038045A (enExample)
CN (1) CN107921130A (enExample)
AU (1) AU2016307955A1 (enExample)
CA (1) CA2995709A1 (enExample)
CL (1) CL2018000422A1 (enExample)
CO (1) CO2018001485A2 (enExample)
CR (1) CR20180105A (enExample)
EA (1) EA201890443A1 (enExample)
EC (1) ECSP18011248A (enExample)
HK (1) HK1249423A1 (enExample)
IL (1) IL257562A (enExample)
MA (1) MA42665A (enExample)
MX (1) MX2018001954A (enExample)
PE (1) PE20181066A1 (enExample)
PH (1) PH12018500363A1 (enExample)
TW (1) TW201718652A (enExample)
WO (1) WO2017030926A1 (enExample)
ZA (1) ZA201800955B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ726520A (en) 2014-05-29 2018-12-21 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
AU2015321546B2 (en) 2014-09-26 2020-09-03 Macrogenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof
TW202208440A (zh) 2015-12-14 2022-03-01 美商宏觀基因股份有限公司 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
EP3585431A4 (en) 2017-02-24 2020-12-16 MacroGenics, Inc. BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING TO CD137 AND TUMOR ANTIGENS, AND THEIR USES
MY200973A (en) 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
MX2020002667A (es) * 2017-09-08 2020-08-03 Maverick Therapeutics Inc Proteinas de unión condicionalmente activadas restringidas.
CN109939231A (zh) * 2017-12-21 2019-06-28 张曼 关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞t24的应用
CN109939126A (zh) * 2017-12-21 2019-06-28 张曼 Cd3×b7h3双特异抗体定向杀伤耐阿霉素膀胱癌细胞pumc-91/adm的应用
CN109939232A (zh) * 2017-12-21 2019-06-28 张曼 关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞pumc-91的应用
CN109939230A (zh) * 2017-12-21 2019-06-28 张曼 关于cd3×b7h3双特异性抗体定向杀伤耐顺铂膀胱癌细胞t24/ddp的应用
CN109971711A (zh) * 2017-12-27 2019-07-05 张曼 关于cd3×b7h3双特异性抗体定向杀伤人膀胱癌细胞的应用
AU2019222666B2 (en) 2018-02-15 2025-12-04 Macrogenics, Inc. Variant CD3-binding domains and their use in combination therapies for the treatment of disease
IL323061A (en) 2018-04-11 2025-10-01 Inhibrx Biosciences Inc Multispecific polypeptide constructs with forced CD3 binding and related methods and uses
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
CN112789294A (zh) 2018-07-24 2021-05-11 印希比股份有限公司 含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法
CN109762068A (zh) * 2018-08-09 2019-05-17 源道隆（苏州）医学科技有限公司 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用
US11208485B2 (en) 2018-10-11 2021-12-28 Inhibrx, Inc. PD-1 single domain antibodies and therapeutic compositions thereof
WO2020076970A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. B7h3 single domain antibodies and therapeutic compositions thereof
TW202033218A (zh) * 2018-12-07 2020-09-16 大陸商江蘇恆瑞醫藥股份有限公司 多特異性蛋白分子
BR112021010026A2 (pt) 2018-12-07 2021-08-17 Jiangsu Hengrui Medicine Co., Ltd. anticorpo cd3 e seu uso farmacêutico
KR102732027B1 (ko) * 2019-07-09 2024-11-20 주식회사 와이바이오로직스 B7-h3(cd276)에 특이적으로 결합하는 항체 및 그의 용도
CN111454357B (zh) * 2019-08-14 2022-03-15 康诺亚生物医药科技（成都）有限公司 一种含有抗体的肿瘤治疗剂的开发和应用
EP3822288A1 (en) * 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
WO2021133653A1 (en) * 2019-12-23 2021-07-01 Macrogenics, Inc. Therapy for the treatment of cancer
CN115380047A (zh) 2020-01-29 2022-11-22 印希比股份有限公司 Cd28单结构域抗体及其多价和多特异性构建体
US20240218069A1 (en) * 2021-04-28 2024-07-04 Lyvgen Biopharma Holdings Limited Bi-specific antibodies comprising anti-b7h3 binding molecules
CN113527493B (zh) * 2021-07-20 2023-10-27 广州爱思迈生物医药科技有限公司 一种b7-h3抗体及其应用
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
CN114539420B (zh) * 2022-01-20 2024-05-17 荣昌生物制药(烟台)股份有限公司 抗b7-h3单克隆抗体、抗b7-h3×cd3双特异性抗体、制备方法及其应用
CN117903311B (zh) * 2024-03-20 2024-10-25 湖南卓润生物科技有限公司 sST2特异性结合蛋白及其制备方法和应用
WO2025245264A1 (en) * 2024-05-21 2025-11-27 Briapro Therapeutics Corp. Anti-b7-h3 antibodies and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150656B2 (en) * 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
ME03440B (me) * 2011-05-21 2020-01-20 Macrogenics Inc Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3
US10851178B2 (en) * 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US9487587B2 (en) * 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
UA116479C2 (uk) * 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2839842A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
IL258521B2 (en) * 2015-10-08 2024-01-01 Macrogenics Inc Combination therapy for the treatment of cancer

Also Published As

Publication number Publication date
IL257562A (en) 2018-04-30
CO2018001485A2 (es) 2018-07-10
PH12018500363A1 (en) 2018-09-10
TW201718652A (zh) 2017-06-01
CN107921130A (zh) 2018-04-17
EA201890443A1 (ru) 2018-09-28
HK1249423A1 (zh) 2018-11-02
ZA201800955B (en) 2018-11-28
CA2995709A1 (en) 2017-02-23
CL2018000422A1 (es) 2018-08-10
KR20180038045A (ko) 2018-04-13
EP3337507A1 (en) 2018-06-27
ECSP18011248A (es) 2018-04-30
US20190002563A1 (en) 2019-01-03
EP3337507A4 (en) 2019-04-24
PE20181066A1 (es) 2018-07-04
WO2017030926A1 (en) 2017-02-23
AU2016307955A1 (en) 2018-03-08
MX2018001954A (es) 2018-11-09
MA42665A (fr) 2018-06-27
JP2018523686A (ja) 2018-08-23

Similar Documents

Publication Publication Date Title
CR20180105A (es) Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos
CL2018001545A1 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
MX391279B (es) Anticuerpos biespecíficos contra cd3 y cd20.
CR20170109A (es) Diacuerpos monovalentes biespecificos que son capaces de unir cd19 y cd3, y usos de los mismos
MX2016001741A (es) Diacuerpos fc monovalentes biespecificos que son capaces de unirse a cd32b y cd79b y usos de los mismos.
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
MX2022014867A (es) Anticuerpos especificos del receptor de poliovirus humano (rvp).
CR20160108A (es) Diacuerpos monovalentes biespecificos que son capaces de unir a cd123 y cd3 y el uso de los mismos
AR109625A1 (es) Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas
CO2018003452A2 (es) Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
MX2016012094A (es) Composiciones de anticuerpos para tratamiento tumoral.
MX2016009555A (es) Proteinas de union y metodos para utilizarlas.
MX380601B (es) Proteínas de unión a cd33 y cd3 biespecíficas.
BR112016030740A2 (pt) diacorpos heterodiméricos biespecíficos e seus usos
MX373245B (es) Anticuerpos cd3 humanizados o quiméricos.
UY35042A (es) Anticuerpos anti-cd3, moléculas de unión a antígeno biespecíficas que se unen a cd3 y cd20, y usos de los mismos.
GT201700131A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
CL2017000311A1 (es) Anticuerpos anti-lag3 y fragmentos de unión a antígeno
MX381046B (es) Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas.
CR20150502A (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización
MX391051B (es) Anticuerpos anti-cd47 y usos de los mismos.
MX2018003183A (es) Proteinas de enlace de antigeno biespecifico y tetraespecifico tetravalentes y usos de las mismas.
CL2019002735A1 (es) Anticuerpos que se unen a steap-1.
CL2016001753A1 (es) Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer
AR101671A1 (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso